secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2026-08-06T20:06:10+00:00
Accession:  0001140361-26-031671
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics raises $10M in private placement; extends cash runway to end of 2028
--------------------------------------------------------------------------------

- Issued 4,761,904 shares at $2.10/share for gross proceeds of $10M; closed August 6, 2026.
- Net proceeds plus existing cash expected to extend cash runway to end of calendar 2028.
- Dual-source manufacturing strategy for GTx-104 initiated; NDA resubmission timing depends on manufacturing readiness.
- Technology transfer to a U.S.-based contract manufacturer is underway.
- Craig-Hallum acted as sole placement agent for the private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126031671/0001140361-26-031671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126031671/ef20079559_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-031671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer